MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2023 International Congress

    A case of idiopathic lower limb dystonia treated with combined use of botulinum toxin type A and phenol nerve block

    E. Bianchini, A. Massimiani, J. Bemporad, M. Giovannelli (Rome, Italy)

    Objective: Here we report a case of focal LLD successfully treated with combined botulinum neurotoxin type A (BoNTA) and Nerve block (NB). Background: Among focal dystonias,…
  • 2023 International Congress

    SYNCHRONIZE: Real-world retrospective safety analysis in patients treated with onabotulinumtoxinA for more than one therapeutic indication

    A. Patel, G. Forde, K. Martinez, A. Mayadev, B. Brucker, K. Becker Ifantides, R. Singh, M. Nelson, I. Yushmanova, S. Battucci, C. Rhyne (Overland Park, USA)

    Objective: Report real-world safety of onabotulinumtoxinA used concomitantly for multiple therapeutic indications. Background: Therapeutic onabotulinumtoxinA is approved in the US for 12 indications, some of…
  • 2023 International Congress

    Long term treatment with botulinum neurotoxin for focal dystonia – effect of dose and dilution

    D. Weise, P. Henn, C. Weise (Stadtroda, Germany)

    Objective: To evaluate the efficacy and safety of the higher dilution rates of Botulinum neurotoxin (BoNT) in focal dystonia. Background: BoNT is the first line…
  • 2023 International Congress

    Diagnostic and treatment burden of dystonia in Turkey: a patient journey map

    R. Yilmaz, N. öksüz, B. Samancı, A. Acarer, M. Ceylan, N. Durmaz-Celik, H. Erdem, S. özkan, H. Hanağası, O. Doğu, C. Akbostancı (Ankara, Turkey)

    Objective: To assess the burden of access to diagnosis and botulinum neurotoxin (BoNT) treatment in Turkish patients with dystonia and hemifacial spasm (PwD/HFS). Background: Diagnostic…
  • 2023 International Congress

    Updates on the Outcomes of Botulinum Toxin Injections in Patients with Lower Limb Dystonia

    M. Wajid, J. Yu, J. Frey, J. Lopes, A. Dave, L. Kugler, T. Stiep, J. Toledo, A. Ramirez-Zamora, A. Rawls, A. Wagle Shukla, I. Malaty (Gainesville, USA)

    Objective: To assess the therapeutic outcomes of botulinum toxin injections (BoNT) in patients with lower limb dystonia (LLD). Background: BoNT to the affected muscle groups…
  • 2023 International Congress

    A novel mobile application for monitoring the response to botulinum toxin in patients with Cervical Dystonia.

    M. Bradley, C. Edwards, R. Borton, A. Ross, F. Molloy (Dublin, Ireland)

    Objective: A pilot study to determine the acceptability of a novel DystoniaDiary application in patients with Cervical Dystonia (CD) attending a specialist clinic. Background: The…
  • 2022 International Congress

    DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia

    D. Yao, L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…
  • 2022 International Congress

    Awake Bruxism, a case series of an underrecognized disorder

    I. Trigo, B. Solano Vila, D. Domínguez (Girona, Spain)

    Objective: We present a series of 3 cases with Awake Bruxism (AB) and frontal dysfunction. Background: AB is an infrequent, daytime form of bruxism, described…
  • 2022 International Congress

    Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

    Objective: We describe a case of pseudodystonia caused by palmaris brevis syndrome. Background: Palmaris brevis (PB) syndrome is a pseudodystonia characterized by spontaneous, involuntary, nonpainful…
  • 2022 International Congress

    Botulinum Toxin Outcomes in Patients with Lower Limb Dystonia

    M. Wajid, J. Frey, L. Kugler, T. Stiep, J. Yu, J. Toledo, J. Lopes, A. Ramirez-Zamora, A. Rawls, A. Wagle Shukla, I. Malaty (Gainesville, USA)

    Objective: To assess botulinum toxin outcomes in patients with lower limb dystonia. Background: One of the most effective treatments for dystonia is botulinum toxin (BoNT)…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 23
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley